3D Printing of Poloxamer 407 Nanogel Discs and Their Applications in Adjuvant Ovarian Cancer Therapy.
3D printing
ovarian cancer
paclitaxel
peritoneal adhesion
poloxamer
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
04 02 2019
04 02 2019
Historique:
pubmed:
5
1
2019
medline:
19
11
2019
entrez:
5
1
2019
Statut:
ppublish
Résumé
Nanogels are attractive biocompatible materials that enable local delivery of multiple drugs. In this study, we demonstrated that 3D printing technology could be used to precisely construct nanogel discs carrying paclitaxel and rapamycin. 3D-printed nanogel disc rounds (12 mm diameter × 1 mm thickness) carrying paclitaxel and rapamycin evaded premature gelation during storage and the initial burst release of the drugs in the dissolution medium. In vivo 3D-printed nanogel discs permitted successful intraperitoneal delivery of paclitaxel and rapamycin in ES-2-luc ovarian-cancer-bearing xenograft mice. They were also shown to be therapeutically effective and capable of preventing postsurgical peritoneal adhesions in the treated xenograft mice.
Identifiants
pubmed: 30608705
doi: 10.1021/acs.molpharmaceut.8b00836
pmc: PMC7357236
mid: NIHMS1603168
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Poloxamer
106392-12-5
Paclitaxel
P88XT4IS4D
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
552-560Subventions
Organisme : NCI NIH HHS
ID : P50 CA094056
Pays : United States
Organisme : NIH HHS
ID : S10 OD020129
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA171651
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA199092
Pays : United States
Organisme : NIH HHS
ID : S10 OD027042
Pays : United States
Organisme : NIH HHS
ID : S10 OD016237
Pays : United States
Références
Obstet Gynecol. 1983 Feb;61(2):189-93
pubmed: 6823360
Expert Opin Drug Saf. 2010 Jul;9(4):515-23
pubmed: 20500029
World J Gastroenterol. 2011 Nov 7;17(41):4545-53
pubmed: 22147959
J Mater Chem B. 2015 Feb 21;3(7):1204-1207
pubmed: 25717377
P T. 2014 Oct;39(10):704-11
pubmed: 25336867
Mol Ther. 2014 Jul;22(7):1310-1319
pubmed: 24569835
World J Gastrointest Oncol. 2010 Feb 15;2(2):102-8
pubmed: 21160928
Dtsch Arztebl Int. 2010 Nov;107(44):769-75
pubmed: 21116396
Anal Chem. 2014 Apr 1;86(7):3240-53
pubmed: 24432804
Med Lett Drugs Ther. 2016 Jun 20;58(1497):78-9
pubmed: 27305068
J Drug Target. 2014 Aug;22(7):669-77
pubmed: 24964052
Int J Surg. 2011;9(8):589-94
pubmed: 21964216
Mayo Clin Proc. 2007 Jun;82(6):751-70
pubmed: 17550756
Adv Drug Deliv Rev. 2017 Jan 1;108:39-50
pubmed: 27001902
Breast Cancer (Auckl). 2011;5:53-65
pubmed: 21603258
Int J Cancer. 2010 Mar 1;126(5):1144-54
pubmed: 19688827
Colorectal Dis. 2007 Oct;9 Suppl 2:25-34
pubmed: 17824967
Int J Pharm. 2016 Feb 29;499(1-2):376-394
pubmed: 26757150
Pharm Res. 2016 Sep;33(9):2298-306
pubmed: 27283829
Molecules. 2015 Nov 13;20(11):20397-408
pubmed: 26580588
J Control Release. 2013 Feb 28;166(1):1-9
pubmed: 23246471
J Pharm Sci. 2013 Aug;102(8):2707-17
pubmed: 23839931
Mol Pharm. 2015 Nov 2;12(11):4077-84
pubmed: 26473653
J Pharm Pharm Sci. 2006;9(3):339-58
pubmed: 17207417